RARE

Ultragenyx Pharmaceutical Inc

Add to Watchlist

Advanced Chart

27.140

-0.52(-1.880%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.460

Open

28.220

VWAP

27.70

Vol

2.32M

Mkt Cap

2.57B

Low

27.010

Amount

64.19M

EV/EBITDA(TTM)

Total Shares

94.54M

2.08B

EV/OCF(TTM)

P/S(TTM)

4.30

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

181.84M

+10.29%

164.23M

+17.73%

161.29M

+9.7%

Estimates Revision

The market is revising Downward the revenue expectations for Ultragenyx Pharmaceutical Inc. (RARE) for FY2025, with the revenue forecasts being adjusted by -1.11% over the past three months. During the same period, the stock price has changed by -30.36%.

Revenue Estimates for FY2025

Revise Downward

-1.11%

In Past 3 Month

Stock Price

Go Down

-30.36%

In Past 3 Month

15 Analyst Rating

204.61% Upside

Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 82.67 USD with a low forecast of 35.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

1 Hold

0 Sell

Strong Buy

204.61% Upside

Current: 27.140

Low

35.00

Averages

82.67

High

136.00

204.61% Upside

Current: 27.140

Low

35.00

Averages

82.67

High

136.00

H.C. Wainwright

Buy

initiated

$80

2025-07-28

New

Reason

H.C. Wainwright

Price Target

$80

2025-07-28

New

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Ultragenyx with a Buy rating and $80 price target. The firm sees an attractive buying opportunity with the shares down 35% year-to-date. The Orbit trial did not fail and the final top-line result is risk-mitigated and should deliver favorable data, the analyst tells investors in a research note.

Morgan Stanley

Overweight

NULL

downgrade

$65 -> $55

2025-07-14

Reason

Morgan Stanley

Price Target

$65 -> $55

2025-07-14

downgrade

Overweight

NULL

Reason

Morgan Stanley lowered the firm's price target on Ultragenyx to $55 from $65 and keeps an Overweight rating on the shares. Ultragenyx's setrusumab strategy for osteogenesis imperfecta is scientifically supported and the chemistry, manufacturing and controls issues for UX111 are believed to be solvable, though these setbacks have heightened clinical and regulatory uncertainty, the analyst tells investors in a research note. The firm sees the market's reaction to the setrusumab update as overdone, with further pressure expected from the complete response letter in the near-term.

BofA

Buy

maintain

$80 -> $79

2025-07-14

Reason

BofA

Price Target

$80 -> $79

2025-07-14

maintain

Buy

Reason

BofA lowered the firm's price target on Ultragenyx to $79 from $80 and keeps a Buy rating on the shares. Ultragenyx announced they have received a complete response letter from the FDA regarding their application for UX111 in Sanfilippo syndrome highlighting that the agency did not have issues with the clinical data package but requested additional information and improvements related to chemistry, manufacturing and controls, the analyst tells investors in a research note. BofA looks for color on the scheduling of the Type A meeting as well as clarity on potential readthrough to the company's other gene therapy programs.

Wells Fargo

Overweight

downgrade

$88 -> $65

2025-07-10

Reason

Wells Fargo

Price Target

$88 -> $65

2025-07-10

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Ultragenyx to $65 from $88 and keeps an Overweight rating on the shares. The firm says that while there is some debate around the update impact on setru's probability of success, Wells doesn't expect the peak sales opportunity to materially change if setru is ultimately approved.

Citi

Buy

maintain

$110

2025-07-10

Reason

Citi

Price Target

$110

2025-07-10

maintain

Buy

Reason

Citi added an \"upside 90-day short-term view\" on Ultragenyx while keeping a Buy rating on the shares with a $110 price target. It recommends buying the selloff following the news that the ORBIT trial will proceed to the final analysis and not be stopped early. Citi believes Ultragenyx is again trading below its base business valuation. The analyst sees an 85% chance that the ORBIT study is successful on the final analysis.

JPMorgan

Overweight

maintain

2025-07-10

Reason

JPMorgan

Price Target

2025-07-10

maintain

Overweight

Reason

JPMorgan views the selloff in shares of Ultragenyx as overdone after the company announced the Phase 3 ORBIT trial of setrusumab in osteogenesis imperfecta will be progressing to the final analysis, which is expected around the end of the year. The firm views the pullback as a "material overreaction," saying it had expected more "sentiment-based downside" in the mid- to high-single digit percentage range. JPMorgan's positive outlook on setrusumab in osteogenesis imperfecta has not changed. On a win in the final analysis, it sees the stock having the potential to go to the mid-$60s to low-$70s. The firm keeps an Overweight rating on Ultragenyx.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE.O) is -5.58, compared to its 5-year average forward P/E of -10.36. For a more detailed relative valuation and DCF analysis to assess Ultragenyx Pharmaceutical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.36

Current PE

-5.58

Overvalued PE

-4.18

Undervalued PE

-16.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.72

Current EV/EBITDA

-6.54

Overvalued EV/EBITDA

-4.00

Undervalued EV/EBITDA

-17.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

11.36

Current PS

3.82

Overvalued PS

18.11

Undervalued PS

4.61

Financials

Annual

Quarterly

FY2025Q1

YoY :

+27.99%

139.29M

Total Revenue

FY2025Q1

YoY :

-13.55%

-142.94M

Operating Profit

FY2025Q1

YoY :

-11.49%

-151.08M

Net Income after Tax

FY2025Q1

YoY :

-22.66%

-1.57

EPS - Diluted

FY2025Q1

YoY :

-10.37%

-182.80M

Free Cash Flow

FY2025Q1

YoY :

-5.33%

79.42

Gross Profit Margin - %

FY2025Q1

-69.93

FCF Margin - %

FY2025Q1

YoY :

-30.84%

-108.46

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 340.69% over the last month.

Sold

0-3

Months

110.3K

USD

3-6

Months

5.6M

USD

6-9

Months

2.1M

USD

0-12

Months

1.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

2.7M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.6M

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 340.69% over the last month.

Sold

0-3

Months

110.3K

USD

3-6

Months

5.6M

USD

6-9

Months

2.1M

USD

0-12

Months

1.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RARE News & Events

Events Timeline

2025-07-14 (ET)

2025-07-14

08:02:41

Ultragenyx announces Health Canada extended approval of Evkeeza

2025-07-11 (ET)

2025-07-11

16:34:43

Ultragenyx receives CRL from FDA for UX111 gene therapy

2025-07-10 (ET)

2025-07-10

08:48:28

Video: Delta jumps, Conagra drops after quarterly earnings reports

News

3.0

07-30Newsfilter

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

4.0

07-28Benzinga

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

4.0

07-28Benzinga

HC Wainwright & Co. Assumes Ultragenyx Pharmaceutical at Buy, Announces Price Target of $80

People Also Watch

FAQ

What is Ultragenyx Pharmaceutical Inc (RARE) stock price today?

The current price of RARE is 27.14 USD — it has decreased -1.88 % in the last trading day.

RARE

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

RARE News & Events

Events Timeline

News

People Also Watch

FAQ

What is Ultragenyx Pharmaceutical Inc (RARE) stock price today?

What is Ultragenyx Pharmaceutical Inc (RARE)'s business?

What is the price predicton of RARE Stock?

What is Ultragenyx Pharmaceutical Inc (RARE)'s revenue for the last quarter?

What is Ultragenyx Pharmaceutical Inc (RARE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Ultragenyx Pharmaceutical Inc (RARE)'s fundamentals?

How many employees does Ultragenyx Pharmaceutical Inc (RARE). have?

What is Ultragenyx Pharmaceutical Inc (RARE) market cap?